Drugs / FL-33 CAR T
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06326021 | Apr 2024 → Jun 2026 overdue | acute myeloid leukemia | Beijing GoBroad Hospital | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FL-33 CAR T | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06326021 ↗ |
| Modality | Cell therapy | “Autologous FL-33 CAR T cells are infused intravenously.” NCT06326021 ↗ |
| Route | Intravenous | “Autologous FL-33 CAR T cells are infused intravenously.” NCT06326021 ↗ |
| Target | CD33 | “Optimised CD33 (FL-33) CAR T Therapy” NCT06326021 ↗ |